DESTINY-Breast 03
Presented by Dr Elisa Agostinetto (Institut Jules Bordet, Brussels, Belgium) & Prof Dr Laurence Buisseret (Institut Jules Bordet, Brussels, Belgium)
Prof Dr Laurence Buisseret and Dr Elisa Agostinetto, medical oncologists at the Institut Jules Bordet in Brussels, Belgium, discuss the updated results of the DESTINY-Breast 03 study.
The DESTINY-Breast 03 trial, a phase 3 study, compared T-DXd to T-DM1 for patients with HER2-positive mBC in the second line. Updated results demonstrated a median PFS of 29 months for T-DXd versus 7.2 months for T-DM1, confirming T-DXd’s position as a preferred second-line treatment. Additionally, OS improved by approximately 10 months with T-DXd. Safety data remained consistent, though interstitial lung disease remains a critical risk, requiring regular monitoring with CT scans.
Looking forward, results from the DESTINY-Breast 09 trial, comparing first-line T-DXd to taxane with trastuzumab and pertuzumab, are anticipated. This could potentially move T-DXd into the first-line setting. Trials in post-neoadjuvant and neoadjuvant settings are also underway, expanding the potential use of T-DXd. The developments highlight a promising future for ADCs in breast cancer treatment.
References:
Hamilton E. et al., ASCO 2024 Abstract #1025
